AN2 Therapeutics, Inc. (ANTX)
$8.71
-0.14 (-1.58%)
Rating:
Recommendation:
-
| Symbol | ANTX |
|---|---|
| Price | $8.71 |
| Beta | 0.000 |
| Volume Avg. | 0.03M |
| Market Cap | 168.998M |
| Shares () | - |
| 52 Week Range | 6.879-23.58 |
| 1y Target Est | - |
| DCF Unlevered | ANTX DCF -> | |
|---|---|---|
| DCF Levered | ANTX LDCF -> | |
| ROE | -42.82% | Strong Sell |
| ROA | -32.78% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 4.20% | Neutral |
| P/E | -4.84 | Strong Sell |
| P/B | 1.60 | Strong Buy |
Latest ANTX news
About
Download (Excel)AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.